Faculty of Chemistry, Adam Mickiewicz University, Umultowska 89b, 61-614, Poznan, Poland.
Magn Reson Chem. 2014 Jan-Feb;52(1-2):10-21. doi: 10.1002/mrc.4028. Epub 2013 Nov 6.
(13)C, (15)N CP/MAS, including (1)H-(13)C and (1)H-(15)N short contact time CP/MAS experiments, and FTIR methods were applied for detailed structural characterization of ansa-macrolides as 3-formylrifamycin SV (1) and its derivatives (2-6) in crystal and in powder forms. Although HPLC chromatograms for 2/CH3 OH and 2/CH3 CCl3 were the same for rifampicin crystals dissolved in respective solvents, the UV-vis data recorded for them were different in 300-375 nm region. Detailed solid state (13)C and (15)N CP/MAS NMR and FTIR studies revealed that rifampicin (2), in contrast to 3-formylrifamycin SV (1) and its amino derivatives (3-6), can occur in pure non-ionic or zwitterionic forms in crystal and in pure these forms or a mixture of them in a powder. Multinuclear CP/MAS and FTIR studies demonstrated also that 3-6 derivatives were present exclusively in pure zwitterionic forms, both in powder and in crystal. On the basis of the solid state NMR and FTIR studies, two conformers of 3-formylrifamycin SV were detected in powder form due to the different orientations of carbonyl group of amide moiety. The PM6 molecular modeling at the semi-empirical level of theory, allowed visualization the most energetically favorable non-ionic and zwitterionic forms of 1-6 antibiotics, strongly stabilized via intramolecular H-bonds. FTIR studies indicated that the originally adopted forms of these type antibiotics in crystal or in powder are stable in standard laboratory conditions in time. The results presented point to the fact that because of a possible presence of two forms of rifampicin (compound 2), quantification of the content of this antibiotic in relevant pharmaceuticals needs caution.
(13)C、(15)N CP/MAS,包括 (1)H-(13)C 和 (1)H-(15)N 短接触时间 CP/MAS 实验,以及傅里叶变换红外(FTIR)方法,被应用于ansa-大环内酯类抗生素 3-甲酰基利福霉素 SV(1)及其衍生物(2-6)在晶体和粉末形式下的详细结构表征。尽管 2/甲醇和 2/氯仿的高效液相色谱(HPLC)图谱对于溶解在各自溶剂中的利福平晶体是相同的,但记录的它们在 300-375nm 区域的紫外-可见(UV-vis)数据是不同的。详细的固态(13)C 和(15)N CP/MAS NMR 和 FTIR 研究表明,与 3-甲酰基利福霉素 SV(1)及其氨基衍生物(3-6)相比,利福平(2)在晶体中可以以纯非离子或两性离子形式存在,而在粉末中则以纯这些形式或它们的混合物形式存在。多核 CP/MAS 和 FTIR 研究还表明,3-6 衍生物仅以纯两性离子形式存在,无论是在粉末中还是在晶体中。基于固态 NMR 和 FTIR 研究,由于酰胺部分羰基的不同取向,在粉末形式下检测到 3-甲酰基利福霉素 SV 的两种构象。在半经验理论水平上的 PM6 分子建模,允许可视化 1-6 种抗生素最具能量优势的非离子和两性离子形式,通过分子内氢键得到强烈稳定。FTIR 研究表明,这些类型抗生素在晶体或粉末中的原始采用形式在标准实验室条件下是稳定的。所呈现的结果表明,由于利福平(化合物 2)可能存在两种形式,因此在相关药物中定量该抗生素的含量需要谨慎。